

# Fabio Cacciapaglia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1187061/publications.pdf>

Version: 2024-02-01

74  
papers

1,069  
citations

516710

16  
h-index

477307

29  
g-index

76  
all docs

76  
docs citations

76  
times ranked

1611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry" by Gianfrancesco M<i> et al</i>. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e159-e159.	0.9	1
2	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 475-480.	2.0	2
3	The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e145-e149.	0.9	10
4	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12
5	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
6	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
7	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. <i>RMD Open</i> , 2022, 8, e001847.	3.8	19
8	Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2022, 49, 334-335.	2.0	9
9	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	2.2	7
10	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 353.	2.5	9
11	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
12	C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. <i>European Journal of Internal Medicine</i> , 2022, 104, 49-54.	2.2	14
13	Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102866.	6.5	10
14	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13363.	3.4	6
15	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
16	Pulmonary arterial hypertension: guidelines and unmet clinical needs. <i>Reumatismo</i> , 2021, 72, 228-246.	0.9	10
17	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021, Publish Ahead of Print, .	0.9	14
18	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , 2021, 40, 3659-3665.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.9	6
20	Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 206, 153-160.	2.6	10
21	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
22	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e122-e122.	0.9	2
23	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patientsâ€™ subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
24	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227.	0.8	1
25	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1147-1148.	0.8	0
26	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e104-e104.	0.9	4
27	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1188-1188.	1.9	9
28	Response to: â€œResponse to: â€œInfluence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patientsâ€ by Fornaro et alâ€™ by Agca et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e106-e106.	0.9	0
29	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1599-1606.	1.9	24
30	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e102-e102.	0.9	0
31	Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13343.	3.4	2
32	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. <i>Clinical and Experimental Immunology</i> , 2020, 201, 200-204.	2.6	6
33	Serum adiponectin levels are associated with presence of carotid plaque in women with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1147-1151.	2.6	4
34	Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 210-218.	1.7	1
35	Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients. <i>Rheumatology</i> , 2020, 59, 1442-1444.	1.9	1
36	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. <i>Clinical Rheumatology</i> , 2019, 38, 2355-2362.	2.2	15

#	ARTICLE	IF	CITATIONS
37	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1309-1317.	2.2	15
38	Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13089.	3.4	8
39	AB0608...TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. , 2019, , .		1
40	AB0245...PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .		0
41	AB0600...APREMILAST EFFECTIVENESS IN REFRACTORY ORAL AND GENITAL ULCERS OF BEHÇET'S DISEASE: DATA FROM REAL LIFE SETTINGS. , 2019, , .		0
42	AB0640...SURVIVAL AND MORTALITY PREDICTORS IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
43	FRI0070...SHORT-TERM INFLAMMATORY AND LIPIDS CHANGES IN RHEUMATOID ARTHRITIS PATIENTS INFLUENCE CARDIOVASCULAR RISK ALGORITHMS: A MONOCENTRIC RETROSPECTIVE STUDY. , 2019, , .		0
44	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. <i>Rheumatology</i> , 2019, 58, 440-440.	1.9	4
45	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.8	10
46	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	30
47	Atherosclerosis and Autoimmunity. <i>Mediators of Inflammation</i> , 2018, 2018, 1-2.	3.0	3
48	Possible role of adipocytokines in systemic sclerosis-associated small pericardial effusion. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 153-158.	1.7	0
49	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 108-114.	3.4	37
50	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. <i>Journal of International Medical Research</i> , 2016, 44, 28-32.	1.0	5
51	Influence of TNF- $\alpha$ inhibition on oxidative stress of rheumatoid arthritis patients. <i>Reumatismo</i> , 2015, 67, 97-102.	0.9	12
52	The Use of an Interferon-Gamma Release Assay as a Biomarker of Response to Anti-TNF-Alpha Treatment. <i>Drug Development Research</i> , 2014, 75, S50-S53.	2.9	8
53	Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. <i>Drug Development Research</i> , 2014, 75, S77-80.	2.9	13
54	New technologies aiding dietary programmes for weight control: the oral glucose spray. <i>Endocrine</i> , 2014, 45, 288-292.	2.3	0

#	ARTICLE	IF	CITATIONS
55	Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. <i>Cardiovascular Toxicology</i> , 2014, 14, 387-392.	2.7	7
56	Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus. <i>Internal and Emergency Medicine</i> , 2013, 8, 705-712.	2.0	41
57	Inflammation and iron metabolism in adult patients with epilepsy: Does a link exist?. <i>Epilepsy Research</i> , 2013, 107, 244-252.	1.6	32
58	Section 3: Rheumatoid Arthritis. <i>Clinical Drug Investigation</i> , 2013, 33, 113-132.	2.2	1
59	The use of a glucose spray device to control progression towards hypoglycaemia. <i>Endocrine</i> , 2012, 42, 442-444.	2.3	1
60	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. <i>Autoimmunity Reviews</i> , 2011, 10, 631-635.	5.8	50
61	Matters of the Heart: The Case of TNF-Targeting Drugs. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2011, 11, 79-87.	3.4	3
62	Apoptosis and Autoimmunity Induced by Clodronate in Systemic Lupus Erythematosus Mononuclear Circulating Cells. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 535-542.	2.1	3
63	Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. <i>Lupus</i> , 2009, 18, 249-256.	1.6	45
64	Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). <i>Autoimmunity Reviews</i> , 2009, 8, 309-315.	5.8	54
65	Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance. <i>Journal of Gastroenterology</i> , 2009, 44, 76-83.	5.1	66
66	Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors. <i>Journal of Rheumatology</i> , 2009, 36, 295-297.	2.0	92
67	Postmeal portal flow variations in HCV-related chronic hepatitis and liver cirrhosis with and without hyperdynamic syndrome. <i>In Vivo</i> , 2008, 22, 509-12.	1.3	9
68	Spontaneous splenorenal shunt in a patient with antiphospholipid syndrome: the first case reported. <i>Lupus</i> , 2007, 16, 56-58.	1.6	7
69	Percutaneous ultrasound-guided ablation of BW7756-hepatoma using ethanol or acetic acid in a rat model. <i>BMC Gastroenterology</i> , 2007, 7, 45.	2.0	2
70	Alexithymia and Neuroendocrine- Immune Response in Patients with Autoimmune Diseases: Preliminary Results on Relationship between Alexithymic Construct and TNF- $\alpha$ Levels. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 208-211.	3.8	28
71	Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation. <i>Journal of Neurochemistry</i> , 2005, 93, 371-382.	3.9	18
72	Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. <i>International Immunopharmacology</i> , 2005, 5, 437-459.	3.8	41

#	ARTICLE	IF	CITATIONS
73	Lack of Effect of Vitamin D Administration during Pregnancy and Early Life on Diabetes Incidence in the Non-obese Diabetic Mouse. <i>Hormone and Metabolic Research</i> , 2004, 36, 620-624.	1.5	23
74	The natural history of insulin content in the pancreas of female and male non-obese diabetic mouse: implications for trials of diabetes prevention in humans. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 394-398.	4.0	4